Display options
Cite
Eckert F, Schaedle P, Zips D, et al. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology. 2018;7(11):e1496881doi: 10.1080/2162402X.2018.1496881.
Eckert, F., Schaedle, P., Zips, D., Schmid-Horch, B., Rammensee, H. G., Gani, C., & Gouttefangeas, C. (2018). Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology, 7(11), e1496881. https://doi.org/10.1080/2162402X.2018.1496881
Eckert, Franziska, et al. "Impact of curative radiotherapy on the immune status of patients with localized prostate cancer." Oncoimmunology vol. 7,11 (2018): e1496881. doi: https://doi.org/10.1080/2162402X.2018.1496881
Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018. PMID: 30393582; PMCID: PMC6208674.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018.

Impact of curative radiotherapy on the immune status of patients with localized prostate cancer.

Oncoimmunology

Franziska Eckert, Philipp Schaedle, Daniel Zips, Barbara Schmid-Horch, Hans-Georg Rammensee, Cihan Gani, Cécile Gouttefangeas

Affiliations

  1. Department of Radiation Oncology, University Hospital Tuebingen, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
  2. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tuebingen, Tuebingen, Germany.
  3. Interfaculty Institute for Cell Biology, Department of Immunology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.
  4. Department for Internal Medicine I, Marienhospital Stuttgart, Stuttgart, Germany.
  5. Institute for Clinical and Experimental Transfusion Medicine, University Hospital Tuebingen, Eberhard-Karls-University, Tuebingen, Germany.

PMID: 30393582 PMCID: PMC6208674 DOI: 10.1080/2162402X.2018.1496881

Abstract

Combination of radiotherapy with immunotherapy has become an attractive concept for the treatment of cancer. The objective of this study was to assess the effect of curative, normofractionated radiotherapy on peripheral immune lymphocytes in prostate cancer patients, in order to propose a rationale for scheduling of normofractionated radiotherapy with T-cell based immunotherapy. In a prospective study (clinicaltrials.gov: NCT01376674), eighteen patients with localized prostate cancer were treated with radiotherapy with or without hormonal therapy. Irradiation volumes encompassed prostate and, in select cases, elective pelvic nodal regions. Blood samples were collected from all patients before, during, and after radiotherapy, as well as from 6 healthy individuals as control. Normofractionated radiotherapy of prostate cancer over eight weeks had a significant influence on the systemic immune status of patients compared to healthy controls. Absolute leukocyte and lymphocyte counts decreased during treatment as did peripheral blood immune subsets (T cells, CD8

Keywords: Prostate cancer; T cells; immunotherapy; peripheral lymphocytes; radiotherapy

References

  1. BJU Int. 2016 Oct;118 Suppl 3:8-13 - PubMed
  2. J Immunother Cancer. 2016 Sep 20;4:51 - PubMed
  3. Int J Oncol. 2014 Apr;44(4):1073-83 - PubMed
  4. Semin Radiat Oncol. 2015 Jan;25(1):11-7 - PubMed
  5. Cancer Lett. 2015 Nov 28;368(2):185-90 - PubMed
  6. Oncoimmunology. 2016 Dec 23;6(2):e1267095 - PubMed
  7. Cytometry A. 2015 Jan;87(1):37-48 - PubMed
  8. Eur Urol. 2011 Dec;60(6):1133-9 - PubMed
  9. J Immunol. 2010 Jul 15;185(2):1330-9 - PubMed
  10. Eur Urol. 2016 Jul;70(1):35-41 - PubMed
  11. Int J Cancer. 2012 Jul 1;131(1):140-9 - PubMed
  12. Strahlenther Onkol. 2017 Aug;193(8):648-655 - PubMed
  13. Immunotherapy. 2012 Apr;4(4):373-82 - PubMed
  14. Cancers (Basel). 2017 Jan 27;9(2):null - PubMed
  15. Clin Cancer Res. 2005 May 1;11(9):3353-62 - PubMed
  16. Cancer. 2009 Aug 15;115(16):3670-9 - PubMed
  17. Prostate. 2003 Sep 1;56(4):270-9 - PubMed
  18. Curr Opin Hematol. 2008 Nov;15(6):555-60 - PubMed
  19. Oncoimmunology. 2017 Apr 28;6(6):e1323161 - PubMed
  20. Clin Transl Radiat Oncol. 2017 Feb 04;2:29-35 - PubMed
  21. Front Oncol. 2012 Oct 26;2:153 - PubMed
  22. J Clin Oncol. 2015 Jun 10;33(17):1889-94 - PubMed
  23. Clin Cancer Res. 2008 Aug 1;14(15):4883-90 - PubMed
  24. Cancer Res. 1976 Jan;36(1):132-7 - PubMed
  25. N Engl J Med. 2012 Mar 8;366(10):925-31 - PubMed
  26. Radiother Oncol. 2010 Jun;95(3):350-8 - PubMed
  27. Cancer J. 2016 Mar-Apr;22(2):130-7 - PubMed
  28. Strahlenther Onkol. 2012 Nov;188(11):975-81 - PubMed
  29. Am J Clin Oncol. 2015 Feb;38(1):90-7 - PubMed
  30. Oncotarget. 2014 Jan 30;5(2):403-16 - PubMed
  31. Lancet Oncol. 2015 Mar;16(3):257-65 - PubMed
  32. J Immunother Cancer. 2016 Dec 20;4:92 - PubMed
  33. Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):120-30 - PubMed
  34. Prostate. 2008 Sep 1;68(12):1319-29 - PubMed
  35. Cytometry B Clin Cytom. 2018 Mar;94(2):342-353 - PubMed
  36. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):84-90 - PubMed
  37. Cancer Biother Radiopharm. 2014 May;29(4):153-61 - PubMed
  38. N Engl J Med. 2017 Dec 21;377(25):2500-2501 - PubMed
  39. N Engl J Med. 2011 Jul 14;365(2):107-18 - PubMed
  40. Prostate. 2009 Jan 1;69(1):70-81 - PubMed
  41. Semin Radiat Oncol. 2015 Jan;25(1):46-53 - PubMed
  42. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55 - PubMed
  43. Urology. 2007 Nov;70(5):931-5 - PubMed
  44. Urol Oncol. 2016 Dec;34(12):548-555 - PubMed
  45. Cancer Immunol Immunother. 2015 Apr;64(4):401-8 - PubMed
  46. Nat Rev Immunol. 2010 Aug;10(8):580-93 - PubMed
  47. Lancet Oncol. 2014 Jun;15(7):700-12 - PubMed
  48. BJU Int. 2012 Feb;109 Suppl 1:22-9 - PubMed
  49. Nat Rev Clin Oncol. 2017 Jun;14(6):365-379 - PubMed
  50. Proc Natl Acad Sci U S A. 2007 May 22;104(21):8959-64 - PubMed
  51. Vaccines (Basel). 2016 Aug 06;4(3):null - PubMed
  52. Radiother Oncol. 2014 Jan;110(1):45-54 - PubMed
  53. J Natl Cancer Inst. 2013 Feb 20;105(4):256-65 - PubMed
  54. Rambam Maimonides Med J. 2015 Jan 29;6(1):e0004 - PubMed
  55. N Engl J Med. 2010 Jul 29;363(5):411-22 - PubMed
  56. Oncotarget. 2016 May 3;7(18):26422-35 - PubMed
  57. J Bone Oncol. 2014 Nov 07;3(3-4):96-102 - PubMed
  58. Lancet Oncol. 2015 Oct;16(13):e498-509 - PubMed
  59. Exp Ther Med. 2010 Sep;1(5):833-839 - PubMed
  60. Eur Urol. 2018 Feb;73(2):178-211 - PubMed
  61. Cancer Lett. 2015 Nov 28;368(2):252-61 - PubMed
  62. Prostate. 2009 Jun 15;69(9):917-27 - PubMed

Publication Types